Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMN
重新利用巴多昔芬对浸润前胰腺癌进行化学预防 IPMN
基本信息
- 批准号:10540747
- 负责人:
- 金额:$ 18.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-14 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAddressAffectAgeAgingBindingCancer EtiologyCaringCell secretionCellsCessation of lifeChemicalsChemopreventionChemopreventive AgentChronicClinicalClinical TrialsComplementComplexDataDevelopmentDiabetes MellitusDuct (organ) structureEffectivenessElderlyEpithelial CellsEpitheliumEstrogen ReceptorsEstrogensExcisionFDA approvedFibroblastsGenetically Engineered MouseGrowthGuidelinesHealth BenefitHeterogeneityHistologicHomeostasisHumanIL-6 inhibitorIL6 Signaling PathwayIL6ST geneImplantIn VitroInduction of ApoptosisInflammationInflammatoryInterleukin 6 ReceptorInterleukin-1Interleukin-6KnowledgeLesionMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMetabolicMetastatic Neoplasm to the LiverModelingMolecularMolecular AnalysisMolecular ProfilingMonitorMorbidity - disease rateMucinous NeoplasmMusMutationNF-kappa BNeoplasm MetastasisOncogenicOperative Surgical ProceduresOralOrganoidsOsteoporosis preventionOxidation-ReductionPancreasPancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPapillaryPathway interactionsPatient CarePatientsPharmaceutical PreparationsPhenotypePhosphorylationPlayPostmenopausePre-Clinical ModelPreventivePreventive measurePreventive therapyPreventive treatmentPrognosisPropertyProteomicsPublishingResearch SubjectsResectableResectedRisk FactorsRoleSTAT3 geneSafetySerumSignal PathwaySignal TransductionSurvival RateTestingTranslatingTumor PromotionWomanantagonistattenuationcancer invasivenesschronic pancreatitisclinical careclinical practicecytokine receptor gp130efficacy evaluationhigh riskhigh risk populationimplantationimprovedin vivoinsightmouse modelneoplastic cellnovelpancreatic cancer cellspancreatic cancer patientspancreatic ductal adenocarcinoma cellpancreatic neoplasmpancreatic stellate cellpancreatic tumorigenesispre-clinicalpremalignantpreventpromoterprotein protein interactionradiological imagingresponsesenescencesuccesstumortumor growthtumor progressiontumorigenic
项目摘要
PROJECT SUMMARY/ABSTRACT
Precancerous lesions of pancreatic ductal adenocarcinoma (PDAC) called pancreatic intraductal papillary
mucinous neoplasms (IPMN) can be detected radiographically, but monitoring and identifying patients who can
benefit from surgical intervention before the development of malignant tumor has been an immense challenge
in the management of patients with IPMN. Here we propose to investigate the feasibility of repurposing FDA-
approved Bazedoxifene as a chemopreventive therapy for patients with IPMN in preclinical models, which may
complement and improve the current care for these patients who are at high-risk for developing PDAC.
Using unbiased computational and chemical screens, we have previously identified Bazedoxifene as a novel
IL-6 signaling antagonist that can directly bind to GP130, a common component of IL-6 receptor complex. IL-
6/STAT3 is a vital oncogenic signaling axis that promotes pancreatic tumorigenesis. Elevated IL-6 level is
associated with inflammation, aging, and poor prognosis and metastasis in pancreatic cancer patients. More
recently, IL-6 secretion stimulated by IL-1-NFkB-JAK/STAT signaling is implicated in activating tumor-
promoting inflammatory cancer associated fibroblast cells (iCAF). While inhibition of IL-6 and STAT3 to
suppress PDAC has been pursued previously, here we propose to explore the uncharted efficacy of
Bazedoxifene (a well-tolerated FDA-approved medication that is prescribed for osteoporosis prevention and
can be taken orally) as a chemopreventive measure for patients who are identified as high-risk for developing
PDAC, specifically those with detectable premalignant IPMN.
To test our novel hypothesis that repurposing Bazedoxifene for chemoprevention would block IPMN
progression to PDAC via inhibition of IL-6 signaling, we will 1) use 3D organoids derived from our unique
mouse model for IPMN and from surgically resected IPMNs from patients to evaluate the functional and
molecular impacts of Bazedoxifene as a chemopreventive agent on epithelial cells (Aim 1); 2) use our IPMN
mouse model and orthotopically implanted murine and human IPMN 3D organoids to investigate the efficacy of
Bazedoxifene as a chemopreventive therapy in vivo (Aims 1 & 2); 3) to investigate if Bazedoxifene also affects
the stromal components, specifically the activation of quiescent fibroblast cells and the interconvertibility
between CAF subtypes in vitro and in vivo (Aims 1 & 2). And lastly 4) since our knowledge of IL-6, metabolic
alterations, CAF subtypes in pancreatic tumorigenesis has been gathered majorly from premalignant PanIN
and invasive PDAC, to address this gap in knowledge, we will also compare and contrast IPMN organoids with
PanIN and PDAC organoids to advance our understanding of the understudied IPMN (Aims 1 & 2).
The success of our application will be transformative to clinical care of patients with IPMN and may be
applicable to other known high-risk groups (i.e. patients with chronic pancreatitis, familial mutations, diabetes)
for pancreatic cancer.
项目摘要/摘要
称为胰腺导管内乳头状癌的胰腺导管腺癌癌前病变
粘液性肿瘤(IPMN)可以通过放射学检查发现,但监测和识别哪些患者可以
在恶性肿瘤发展之前接受手术干预一直是一个巨大的挑战
在IPMN患者的管理中。在这里,我们建议研究重新调整FDA用途的可行性-
在临床前模型中批准巴多昔芬作为IPMN患者的化学预防治疗,这可能
补充和改善目前对这些患有PDAC高危患者的护理。
利用无偏的计算和化学筛选,我们以前已经确定巴多昔芬是一种新的
IL-6信号拮抗剂,可直接与IL-6受体复合体的常见成分gp130结合。伊尔-
6/STAT3是促进胰腺肿瘤发生的重要致癌信号轴。IL-6水平升高是
与胰腺癌患者的炎症、衰老、预后不良和转移有关。更多
最近,IL-1-NFkB-JAK/STAT信号刺激的IL-6分泌与激活肿瘤相关。
促进炎性癌症相关成纤维细胞(ICAF)。而对IL-6和STAT3的抑制作用
抑制PDAC之前一直在进行,在这里我们建议探索未知的疗效
巴多昔芬(一种耐受性良好的FDA批准的药物,用于预防骨质疏松症和
可以口服)作为一种化学预防措施,用于被确定为高危疾病的患者
PDAC,特别是那些可检测到癌前IPMN的患者。
为了验证我们的新假设,即重新用于化学预防的巴多昔芬将阻断IPMN
通过抑制IL-6信号向PDAC发展,我们将1)使用来自我们独特的
建立小鼠IPMN模型和手术切除患者的IPMN,以评估其功能和功能
巴多昔芬作为化学预防药物对上皮细胞的分子影响(目标1);2)使用我们的IPMN
小鼠模型及原位植入小鼠和人IPMN 3D有机化合物的疗效观察
巴多昔芬作为体内化学预防疗法(AIMS 1和2);3)研究巴多昔芬是否也影响
间质成分,特别是静止的成纤维细胞的激活和相互转化
体外和体内CAF亚型之间的差异(目标1和2)。最后4)自从我们知道了IL-6,新陈代谢
胰腺癌前病变、CAF亚型在胰腺癌发生中的作用
和侵入性PDAC,为了解决这一知识差距,我们还将比较和对比IPMN有机物和
Panin和PDAC有机化合物,以促进我们对未被研究的IPMN的理解(目标1和2)。
我们的成功应用将对IPMN患者的临床护理产生变革,并可能
适用于其他已知的高危人群(即慢性胰腺炎、家族性突变、糖尿病患者)
治疗胰腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Iok In Christine Chio其他文献
Iok In Christine Chio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Iok In Christine Chio', 18)}}的其他基金
Characterizing the role of MSRA in pancreatic tumorigenesis
表征 MSRA 在胰腺肿瘤发生中的作用
- 批准号:
10658248 - 财政年份:2023
- 资助金额:
$ 18.35万 - 项目类别:
Studying the role of eIF4A in Pancreatic Cancer
研究 eIF4A 在胰腺癌中的作用
- 批准号:
10640183 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Studying the role of eIF4A in Pancreatic Cancer
研究 eIF4A 在胰腺癌中的作用
- 批准号:
10529955 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMN
重新利用巴多昔芬对浸润前胰腺癌进行化学预防 IPMN
- 批准号:
10363411 - 财政年份:2021
- 资助金额:
$ 18.35万 - 项目类别:
NRF2-dependent redox signaling in pancreatic cancer
胰腺癌中 NRF2 依赖性氧化还原信号传导
- 批准号:
10348724 - 财政年份:2020
- 资助金额:
$ 18.35万 - 项目类别:
NRF2-dependent redox signaling in pancreatic cancer
胰腺癌中 NRF2 依赖性氧化还原信号传导
- 批准号:
10559572 - 财政年份:2020
- 资助金额:
$ 18.35万 - 项目类别:
NRF2-dependent redox signaling in pancreatic cancer
胰腺癌中 NRF2 依赖性氧化还原信号传导
- 批准号:
9980117 - 财政年份:2020
- 资助金额:
$ 18.35万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Research Grant














{{item.name}}会员




